Attendances for the 20% of the population living in the most deprived areas also account for 27% of all A&E attendances.
News
Novartis’ MS drug trumps Sanofi’s Aubagio
The drug was able to reduce annualised MS relapse rates by 50.5% and 58.5% in the ASCLEPIOS I and II trials.
Medtronic, Novo Nordisk enter digital diabetes solutions deal
The new collaboration will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring devices from Medtronic.
ICR discovers major biological processes in myeloma development
The discovery could aid the development of more personalised treatments for myeloma patients.
NICE, PHE publish antimicrobial prescribing guidance on pneumonia
New recommendations have been added to highlight that antibiotic treatment should be started as soon as possible – no more than four hours after diagnosis and one hour if sepsis is suspected.
BioMarin’s Brineura made available on NHS
The £500,000 per patient drug was deemed too costly for use in February 2018.
FDA approves Nucala
The treatment was also recently made available in two new formulations in the UK, a pre-filled pen and a pre-filled syringe.
Ipsen opens new Milton Park research centre
The centre will enable scientists to “better support the development of current and future biological medicines.”
‘Collaborative vision’ could speed up access to medicines
Currently less than 50% of orphan medicines are routinely funded in England, Scotland and Wales.
First patient dosed in Fabry Disease gene therapy trial
The study is the first clinical-stage adeno-associated virus (AAV) gene therapy study globally for Fabry Disease.
Seven new data hubs to be rolled out across UK
The hubs will be the home of “cutting-edge research” for health discoveries.
Keyhole hysterectomy surgery ‘safer and more effective’
The technique removes just part of the uterus using a keyhole surgery.
Final chance to enter into the 2019 Communications Team of the Year & Marketer of the Year!
Entry for the 2019 Communications Team of the Year and Marketer of the Year competitions will be closing for entry on Monday the 16th of September.
Launch of health technology accelerator programme
Just 15 participants were selected for the The Greater Manchester Future of Health Challenge.
Mavenclad real-world data shows sustained efficacy
75% of treated MS patients showed no disability progression at five years post treatment.
